Preterm birth is defined as occurring before 37 weeks of gestation, and it has a US prevalence of 10% . Three percent of preterm births are early preterm, between 20-34 weeks gestation. As shown below, preterm births are associated Analyst's Disclosure:I/we have a beneficial long position in the shares of SERA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I ...

A downtrend has been apparent in Sera Prognostics, Inc. (SERA) lately with too much selling pressure. The stock has declined 43.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicato ...

SALT LAKE CITY, May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences:William Blair 45th Annual Growth Stock ConferenceDate: June 3 – 5, 20251X1 Meetings OnlyDoug Fisher, M.D., Strategic Advisor to Sera and former Chief Business Offic ...

纪要涉及的公司 Sera Prognostics (SERA) 纪要提到的核心观点和论据 1. **市场需求大**：每年有360万妈妈分娩，其中很大一部分是首次分娩，此前除了有早产史和短宫颈外，没有好的早产预测方法，一半早产妈妈无风险因素，医生难预测 [1] 2. **审批情况**：早产测试是实验室开发测试（LDT），由CAP和CLIA监管，非FDA监管，FDA曾欲监管但败诉撤回规则，公司获相关机构全面认证，未来FDA若监管公司仍有优势，但LDT获FDA批准更难 [4][6][7] 3. **报销优势**：与国家支付方Elevance合作开展PRIME试验，展示测试和干预措施对母婴健康及成本的积极影响，吸引商业和医疗补助计划关注，有望获得双方覆盖；有750美元的医疗保险代码，医疗补助计划已开始试点 [9][10][14] 4. **市场潜力大**：排除短宫颈和有早产史的妈妈，目标市场（TAM）约320万女性，是数十亿美元的机会 [16] 5. **市场策略**：针对约4万名妇产科医生（OBGYN），先在3 - 5个州采取针对性策略，选择早产评级低、有意见领袖和良好支付方关系的州，创造势头后再扩展 [17][18] 6. **产能情况**：位于犹他州盐湖城的实验室技术先进，现有投资可支持未来几年扩大规模，运行数十万次测试 [19] 7. **成本与利润**：预计随着产量增加，毛利率约80%，市场渗透率提高后可将测试转移到现有通用平台 [20] 8. **销售团队**：正在招聘，新聘请首席商务官Lee Anderson，他有丰富行业经验，将助力团队发展 [22] 9. **资金状况**：刚筹集5700万美元，现有资金2.15亿美元，到2028年底约4年可实现盈利，年现金消耗率2500 - 3000万美元，有扩大运营支出空间 [23][24] 10. **研发管线**：绘制了孕期妈妈血液中300多种蛋白质图谱，有丰富女性健康产品管线，如先兆子痫、妊娠糖尿病等，已开始相关研究并收集大量样本 [29] 11. **临床效果与经济优势**：PRIME研究显示可使五分之一婴儿避免入住新生儿重症监护室（NICU）；Elevance模型显示对4万名孕妇应用测试，每位受筛成员可节省1600美元；筛查3 - 4名妈妈可节省1天NICU费用（平均4500美元，最高20000美元），比经阴道超声更有效且成本低 [31][32][34] 12. **价格策略**：定价750美元是为确保所有有需要的妈妈能使用该测试，考虑到医疗补助计划削减预算的情况 [38] 13. **市场反应**：妇产科医生对测试很感兴趣，公司计划发布3 - 4篇数据相关文章，与临床社区分享测试效果和干预效率 [39] 14. **催化剂时间线**：今年重要催化剂包括即将发布的研究结果、医疗补助计划的进展和测试量的增长 [41][42] 15. **收入指引**：待在3 - 5个州取得良好进展并能准确预测测试量时，将开始提供收入指引 [43] 其他重要但是可能被忽略的内容 - 干预措施包括低剂量阿司匹林、孕酮和护理管理，低剂量阿司匹林81毫克，每日阴道孕酮，护理管理为每周护士电话回访，可将护理资源集中于有需要的妈妈 [40] - 早产婴儿平均NICU住院时间超10天，10%的婴儿早产，医疗补助计划中43%的妈妈分娩，分娩相关费用占医疗补助住院费用的27%，全国早产成本超250亿美元 [35] - 经阴道超声筛查需每2 - 4周监测一次，孕期监测4 - 8次，每次3 - 800美元，需筛查150名妈妈才能避免1次NICU入院，而该测试只需41名妈妈 [36]

Sera Prognostics, Inc. (SERA) has been beaten down lately with too much selling pressure. While the stock has lost 30.5% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscil ...

"Lee is a highly accomplished leader with commercial expertise in fostering innovation, supporting continuous optimization and driving sales and offers a history of strong performance within the healthcare and diagnostics space," said Zhenya Lindgardt, President and CEO of Sera Prognostics. "With Sera now in the commercial phase following the strong results of our pivotal PRIME study, Lee will play a critical role in expanding adoption and sales of our PreTRM Test and we enthusiastically welcome Lee to our ...

This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this company would post a loss of $0.23 per share when it actually produced a loss of $0.25, delivering a surprise of -8.70%. Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items. There are no easy answers to this key questi ...

Sera Prognostics (SERA) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Company Participants Peter Denardo - PresidentZhenya Lindgardt - President & CEOAustin Aerts - Chief Financial Officer Conference Call Participants None - AnalystDaniel Brennan - Analyst Operator Good afternoon, and welcome to the SeraPrognostics Conference Call to Review First Quarter Fiscal Year twenty twenty five Results. At this time, all participants are in a listen only mode. We will be facilitating a question and answer session to ...

Sera Prognostics (SERA) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Speaker0 Good afternoon, and welcome to the SeraPrognostics Conference Call to Review First Quarter Fiscal Year twenty twenty five Results. At this time, all participants are in a listen only mode. We will be facilitating a question and answer session toward the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Peter DeNardo of Capcom Partners for a few introduc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40606 SERA PROGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 26-1911522 | | --- | --- | | (State or other jur ...